Chris Howerton
Stock Analyst at Jefferies
(2.68)
# 2,184
Out of 5,090 analysts
69
Total ratings
46.3%
Success rate
19.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $5.98 | +33.78% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $34.56 | +128.59% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $2.68 | +49.25% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $2.49 | +301.61% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $2.07 | +16,904.83% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $17.56 | +4,000.23% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.51 | -66.89% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $22.98 | -56.48% | 1 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $21.34 | -48.45% | 3 | Nov 30, 2022 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $23.63 | +69.28% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $39.83 | +53.15% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $149.22 | -39.69% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $5.39 | +122.63% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.70 | +2,770.68% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $29.45 | +124.11% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.33 | +312.76% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.08 | +1,844.44% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $0.95 | +2,211.65% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $27.44 | -23.47% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $16.66 | +3,381.39% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.74 | +3,348.28% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $86.11 | -81.42% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $89.65 | -69.88% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $4.27 | +28,003.04% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $5.98
Upside: +33.78%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $34.56
Upside: +128.59%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $2.68
Upside: +49.25%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $2.49
Upside: +301.61%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $2.07
Upside: +16,904.83%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $17.56
Upside: +4,000.23%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.51
Upside: -66.89%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $22.98
Upside: -56.48%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $21.34
Upside: -48.45%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $23.63
Upside: +69.28%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $39.83
Upside: +53.15%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $149.22
Upside: -39.69%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $5.39
Upside: +122.63%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $0.70
Upside: +2,770.68%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $29.45
Upside: +124.11%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $5.33
Upside: +312.76%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.08
Upside: +1,844.44%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $0.95
Upside: +2,211.65%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $27.44
Upside: -23.47%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $16.66
Upside: +3,381.39%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.74
Upside: +3,348.28%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $86.11
Upside: -81.42%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $89.65
Upside: -69.88%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $4.27
Upside: +28,003.04%